Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Liver Disease: Supporting Liver Health with Modern Cell Care
Transcript
- 0:00SPEAKER_00: Welcome to the Cyrona Cell Podcast.
- 0:02SPEAKER_01: Thanks for having me.
- 0:02SPEAKER_01: It's great to be here.
- 0:03SPEAKER_00: Yeah, we've got a really fascinating one for you today.
- 0:06SPEAKER_00: Today we're taking a deep dive into an exciting frontier of regenerative medicine, specifically looking at sources from Syrona Cell.
- 0:14SPEAKER_01: Right, the center over in Malaysia.
- 0:16SPEAKER_00: Exactly.
- 0:17SPEAKER_00: A doctor-led center in Kuala Lumpur, Malaysia.
- 0:20SPEAKER_00: We are focusing specifically on stem cell therapy for liver disease.
- 0:24SPEAKER_01: It's a huge topic.
- 0:25SPEAKER_00: It really is.
- 0:26SPEAKER_00: And look, I know that when we hear the word stem cells, the internet throws just a ton of hype at us.
- 0:32SPEAKER_01: Oh, definitely.
- 0:32SPEAKER_01: A lot of noise out there.
- 0:33SPEAKER_00: Yeah, just flashy headlines and miracle promises.
- 0:36SPEAKER_00: So the goal today for you, the listener, is to cut through all that noise.
- 0:40SPEAKER_00: We want to skip the miracle promises entirely and understand the actual science of how this works.
- 0:45SPEAKER_01: Aaron Powell And what's fascinating here is how the focus has really shifted.
- 0:49SPEAKER_01: I mean, for a long time, the public perception of stem cells was stuck in this sort of experimental Wild West era.
- 0:55SPEAKER_00: Aaron Powell Like science fiction almost.
- 0:57SPEAKER_01: Exactly.
- 0:58SPEAKER_01: But when you look at the real-world clinical use now, it's completely different.
- 1:03SPEAKER_01: We are talking about highly structured, medically supervised cellular care.
- 1:07SPEAKER_01: Right.
- 1:08SPEAKER_01: It's moved away from looking for a magic bullet to applying really serious methodical biological science.
- 1:14SPEAKER_01: Trevor Burrus, Jr.
- 1:14SPEAKER_00: Okay.
- 1:14SPEAKER_00: Before we actually get into understanding how stem cells treat the liver, we need to understand the environment where this treatment happens and the philosophy behind it.
- 1:23SPEAKER_01: Which is so important for context.
- 1:25SPEAKER_00: Yeah, because vetting the center is like vetting a contractor before letting them touch your house.
- 1:30SPEAKER_00: You want to know their safety standards before they start knocking down walls.
- 1:34SPEAKER_01: That is a perfect way to put it.
- 1:35SPEAKER_00: So Sorona cell is based in Kuala Lumpur, but their reach is massive.
- 1:39SPEAKER_00: They're drawing international patients from all over, like Australia in the Middle East.
- 1:44SPEAKER_01: Which tells you a lot about the demand for this specific standard of care.
- 1:48SPEAKER_00: For sure.
- 1:49SPEAKER_00: And I love this detail from the sources the name Sorona actually comes from a Celtic goddess of health and protection.
- 1:54SPEAKER_01: Oh, wow.
- 1:55SPEAKER_01: Really?
- 1:56SPEAKER_00: Yeah.
- 1:56SPEAKER_00: It's symbolic of their focus on safe, science-led care rather than just quick fixes.
- 2:02SPEAKER_01: That makes total sense.
- 2:03SPEAKER_01: And you see that protective philosophy and how they build their medical team too.
- 2:07SPEAKER_00: Right, because it's not just one guy with a syringe.
- 2:09SPEAKER_01: No, not at all.
- 2:10SPEAKER_01: It's a highly diverse medical team.
- 2:12SPEAKER_01: You've got experts in internal medicine, neurology, rehabilitation, and sports medicine.
- 2:18SPEAKER_00: Wait, I have to jump in there.
- 2:19SPEAKER_00: Sports medicine and neurology.
- 2:22SPEAKER_00: If someone is going in for liver disease, why do they have a neurologist or a sports doctor on the team?
- 2:27SPEAKER_01: Well, it sounds counterintuitive, but they treat a lot of different things like neurological, autoimmune, joint metabolic, and anti-aging conditions.
- 2:36SPEAKER_00: Okay, but how does that relate to the liver?
- 2:38SPEAKER_01: Because the body is a whole system.
- 2:39SPEAKER_01: When a major organ fails, it affects everything.
- 2:42SPEAKER_01: You might have neurological confusion from toxins, or you might need physical rehab because of muscle wasting.
- 2:49SPEAKER_01: Having that broad team means they can safely manage the patient's entire physiological state, not just focus blindly on one organ.
- 2:56SPEAKER_00: That makes a lot of sense.
- 2:57SPEAKER_00: Now, as for the actual cells they use, the sources are very clear.
- 3:01SPEAKER_00: They exclusively use ethically sourced umbilical cord-derived cells.
- 3:05SPEAKER_01: Specifically the WJM SCs.
- 3:08SPEAKER_00: All right, the Wharton's jelly mesenchymal stem cells.
- 3:10SPEAKER_00: And these are from healthy term deliveries with full donor consent.
- 3:14SPEAKER_01: Yes.
- 3:14SPEAKER_01: And the lab standards are critical here.
- 3:16SPEAKER_01: They process these in BSL2 laboratories under CGMP and ISO 9001 standards.
- 3:23SPEAKER_00: Which means, well, it means it's incredibly strict, right?
- 3:26SPEAKER_01: Extremely strict.
- 3:27SPEAKER_01: It's the difference between a medical grade therapeutic and a complete gamble.
- 3:31SPEAKER_01: They are testing for purity, viability, identity.
- 3:34SPEAKER_01: You are getting a highly characterized biological product.
- 3:38SPEAKER_00: But wait, I have to ask about the controversy.
- 3:40SPEAKER_00: If they are so ethical and they don't use embryonic cells, why do people still associate stem cell therapy with all those massive debates?
- 3:47SPEAKER_01: It's mostly just a lag in public awareness.
- 3:50SPEAKER_01: The early research decades ago focused heavily on embryonic cells.
- 3:54SPEAKER_01: Right.
- 3:54SPEAKER_00: That was all over the news in the early 2000s.
- 3:56SPEAKER_01: Exactly.
- 3:57SPEAKER_01: But modern real-world clinical use relies on these MSCs from the umbilical cord.
- 4:02SPEAKER_01: They are ethical, they are safer, they're easier to prepare, and they are incredibly effective at sending healing signals.
- 4:08SPEAKER_00: And they explicitly do not use embryonic stem cells or those experimental pluripotent stem cells.
- 4:14SPEAKER_01: No, because pluripotent cells are unpredictable.
- 4:17SPEAKER_01: You don't want a cell that can turn into anything, because it might turn into something harmful.
- 4:22SPEAKER_01: MSCs are safe and targeted.
- 4:24SPEAKER_00: Okay, let's unpack this.
- 4:26SPEAKER_00: Because now that we know who is delivering the care and what cells they use, let's look at the specific organ we are trying to rescue today.
- 4:34SPEAKER_00: The liver.
- 4:35SPEAKER_01: The body's ultimate multitasker.
- 4:37SPEAKER_00: Right.
- 4:37SPEAKER_00: It's filtering toxins, storing energy, digesting food.
- 4:41SPEAKER_00: But the way I think about it, the liver is essentially a city's central water filtration plant.
- 4:46SPEAKER_01: Oh, that's a brilliant analogy.
- 4:48SPEAKER_00: When it gets injured long term, healthy tissue is replaced by scar tissue.
- 4:53SPEAKER_00: So it's like the filtration plant gets clogged with concrete.
- 4:56SPEAKER_01: Yes.
- 4:56SPEAKER_01: Clinically we call that fibrosis, which leads to cirrhosis and eventually decompensation.
- 5:01SPEAKER_00: And when it's clogged with concrete, the whole city's water supply gets toxic.
- 5:06SPEAKER_00: And the problem is you can't just order a new plant on Amazon.
- 5:09SPEAKER_00: Waiting for a transplant takes a really long time.
- 5:12SPEAKER_01: It can take years.
- 5:13SPEAKER_01: And patients deteriorate significantly while they wait.
- 5:15SPEAKER_00: The sources also mention something called acute on chronic liver failure.
- 5:20SPEAKER_01: Yes.
- 5:20SPEAKER_01: That is a highly dangerous scenario.
- 5:22SPEAKER_00: It's like a sudden crash, right?
- 5:24SPEAKER_00: Triggered by an infection or alcohol or bleeding.
- 5:28SPEAKER_00: And it leads to terrible weakness, confusion, swelling, shortness of breath.
- 5:32SPEAKER_01: It's a full system emergency.
- 5:34SPEAKER_01: And doctors track this severity using very specific tools.
- 5:38SPEAKER_01: They look at blood tests, scans, MLAD trends.
- 5:41SPEAKER_00: The model for end-stage liver disease, right?
- 5:44SPEAKER_01: Exactly.
- 5:44SPEAKER_01: And also child Pew scores.
- 5:46SPEAKER_01: These track how close the liver is to a total shutdown.
- 5:50SPEAKER_01: And like you said, liver transplants are the standard for end-stage cases, but they are incredibly hard to get.
- 5:55SPEAKER_00: Which leaves people in this agonizing waiting game.
- 5:58SPEAKER_01: And this is exactly why regenerative medicine is so vital.
- 6:01SPEAKER_01: It's not about replacing the filtration plant immediately.
- 6:04SPEAKER_00: It's about buying time.
- 6:05SPEAKER_01: Yes, providing critical supportive care to keep the plant functioning while the patient waits for a transplant or undergoes standard treatments.
- 6:12SPEAKER_00: Okay, so if we aren't swapping out the liver, how do these tiny little cells actually help a failing organ?
- 6:19SPEAKER_01: Well, first, it's important to remember that stem cell therapy is an adjunct.
- 6:22SPEAKER_00: Meaning it doesn't replace standard specialist care.
- 6:25SPEAKER_01: Correct.
- 6:26SPEAKER_01: You still need your hepatologist.
- 6:27SPEAKER_01: The cells act like a support team.
- 6:30SPEAKER_01: They don't magically become a new liver.
- 6:33SPEAKER_00: Here's where it gets really interesting.
- 6:35SPEAKER_00: So they aren't replacement parts.
- 6:37SPEAKER_00: They are more like highly trained emergency managers walking into a disaster zone.
- 6:41SPEAKER_01: Yes, exactly.
- 6:42SPEAKER_00: They aren't laying the bricks themselves, they're barking orders to the local immune system to stop panicking, put out the fire, and rebuild.
- 6:50SPEAKER_01: If we connect this to the bigger picture, the liver actually naturally wants to repair itself.
- 6:55SPEAKER_00: Right.
- 6:55SPEAKER_00: It's known for regenerating.
- 6:56SPEAKER_01: Yes.
- 6:57SPEAKER_01: But in severe disease, it gets completely overwhelmed by inflammation and scarring.
- 7:03SPEAKER_01: The stem cells simply boost the body's innate regenerative capacity.
- 7:07SPEAKER_00: So what are the actual mechanisms?
- 7:09SPEAKER_00: How do they boost it?
- 7:10SPEAKER_01: There are three main ways.
- 7:11SPEAKER_01: First, they calm immune overactivity and reduce that massive inflammation.
- 7:15SPEAKER_00: Putting out the fire.
- 7:16SPEAKER_01: Exactly.
- 7:17SPEAKER_01: Second, they support blood flow.
- 7:19SPEAKER_01: They help restore oxygen and nutrients to the damaged tissue.
- 7:22SPEAKER_00: Okay.
- 7:23SPEAKER_00: And the third?
- 7:24SPEAKER_01: They release critical growth signals, specifically something called hepatocyte growth factor.
- 7:28SPEAKER_00: Hepatocytes being the liver cells.
- 7:30SPEAKER_01: Right.
- 7:30SPEAKER_01: This encourages the existing surviving liver cells to start multiplying and repairing the tissue.
- 7:36SPEAKER_00: So the goal is to restore that healthy tissue balance.
- 7:39SPEAKER_01: Yes, which leads to a steadier appetite, less swelling, and improved lab trends over time.
- 7:45SPEAKER_00: Okay.
- 7:45SPEAKER_00: Analogies are great.
- 7:46SPEAKER_00: But for you listening, the real question is: does this actually work in humans?
- 7:51SPEAKER_01: It's a fair question.
- 7:52SPEAKER_00: We aren't just talking about mice in a lab, right?
- 7:54SPEAKER_00: Right.
- 7:54SPEAKER_00: Let's look at the actual clinical data from the sources.
- 7:57SPEAKER_01: And there is some really robust human evidence out there.
- 8:01SPEAKER_01: For example, a major study from Sun Yatsen University in China.
- 8:05SPEAKER_00: What were they looking at exactly?
- 8:06SPEAKER_01: They studied patients with hepatitis B-related liver failure and cirrhosis.
- 8:11SPEAKER_01: They gave them umbilical cord-derived MSEs and tracked their lab markers.
- 8:15SPEAKER_00: And what I found fascinating in that source was the improvement in bilirubin trends.
- 8:21SPEAKER_01: Yes, bilirubin clearance improved significantly.
- 8:24SPEAKER_00: And their MLD scores got better too.
- 8:27SPEAKER_00: But the key finding was that longer treatment courses were linked to much better sustained improvements.
- 8:32SPEAKER_01: Which means this isn't a one-off miracle injection.
- 8:35SPEAKER_01: It requires a structured, ongoing approach.
- 8:37SPEAKER_00: Right.
- 8:38SPEAKER_00: And there was another study, too, from Chengdu Military General Hospital.
- 8:41SPEAKER_01: Yes, also in China.
- 8:43SPEAKER_01: They evaluated these cells for decompensated cirrhosis, which is a very severe stage.
- 8:49SPEAKER_00: And they use it alongside conventional care.
- 8:51SPEAKER_01: Right, exactly.
- 8:53SPEAKER_01: And the patient saw early relief from abdominal distention.
- 8:56SPEAKER_00: That's the painful swelling in the belly.
- 8:58SPEAKER_01: Yes, caused by fluid leaking out because the liver isn't making enough proteins.
- 9:03SPEAKER_01: But after the stem cells, they saw sustained increases in albumin and prealbumin over time.
- 9:10SPEAKER_00: Which means the liver started doing its job again.
- 9:13SPEAKER_00: And crucially, there were no serious side effects reported.
- 9:17SPEAKER_01: That safety profile is incredibly important.
- 9:19SPEAKER_00: Now, this all sounds incredibly promising, but I have to play devil's advocate for a minute.
- 9:23SPEAKER_01: Sure, go ahead.
- 9:24SPEAKER_00: With results like this, does this mean everyone with a failing liver should immediately book a flight to Malaysia?
- 9:29SPEAKER_01: Not necessarily, no.
- 9:31SPEAKER_01: We really have to temper expectations here.
- 9:33SPEAKER_00: How so?
- 9:33SPEAKER_01: Well, Cyarnacell is completely transparent about this.
- 9:36SPEAKER_01: If a patient is in a severe acute crisis, they might not be a fit.
- 9:41SPEAKER_00: So if they're crashing in the ICU, it's too late for this.
- 9:43SPEAKER_01: Usually, yes.
- 9:45SPEAKER_01: The patients who fare the best are those with chronic liver illness who still maintain some level of stable daily function.
- 9:52SPEAKER_00: Aaron Powell Which explains why their patient screening is so strict.
- 9:54SPEAKER_01: Very strict.
- 9:55SPEAKER_01: They conduct rigorous reviews of malel trends, medication, and lifestyle.
- 10:00SPEAKER_00: Like alcohol use and nutrition.
- 10:01SPEAKER_01: Exactly.
- 10:02SPEAKER_01: If you are actively drinking, you are just pouring fuel on the fire.
- 10:05SPEAKER_01: The cells can't outwork active destruction.
- 10:08SPEAKER_00: Makes total sense.
- 10:10SPEAKER_00: So assuming a patient passes that screening and is a good candidate, what does the actual process look like?
- 10:15SPEAKER_01: It's surprisingly straightforward.
- 10:17SPEAKER_01: It's a four-step process.
- 10:18SPEAKER_00: Right.
- 10:18SPEAKER_00: The sources say step one is the medical evaluation.
- 10:21SPEAKER_01: Yes, where that diverse team reviews your scans, your meds, and sets realistic aims for the therapy.
- 10:27SPEAKER_00: And step two is preparation.
- 10:29SPEAKER_01: Which goes back to the lab standards.
- 10:31SPEAKER_01: Strict lab testing of the cells for strength, purity, and identity before they ever reach the patient.
- 10:36SPEAKER_00: And then the administration.
- 10:38SPEAKER_00: I think a lot of people picture open surgery or injecting directly into the liver.
- 10:42SPEAKER_01: No, not at all.
- 10:43SPEAKER_01: It's minimally invasive.
- 10:45SPEAKER_01: Usually it's just an IV drip.
- 10:46SPEAKER_01: You are relaxing in a chair.
- 10:48SPEAKER_00: No open surgery required.
- 10:50SPEAKER_00: The cells just find their way.
- 10:52SPEAKER_01: Yes, they naturally home in on the signals of inflammation coming from the liver.
- 10:56SPEAKER_00: That is wild.
- 10:57SPEAKER_00: And then step four is the monitoring and follow-up.
- 11:01SPEAKER_01: Right.
- 11:01SPEAKER_01: Tracking the patient's energy, sleep, swelling, and getting regular lab tests to see how the organ is responding.
- 11:07SPEAKER_00: So what does this all mean when we talk about pushing the envelope?
- 11:11SPEAKER_00: Because the sources mentioned an upgrade to this whole process.
- 11:14SPEAKER_01: Ah, yes.
- 11:15SPEAKER_01: Exosome therapy.
- 11:16SPEAKER_00: Right.
- 11:17SPEAKER_00: What exactly are exosomes?
- 11:18SPEAKER_01: They are essentially tiny messenger packets that are released by the stem cells.
- 11:23SPEAKER_00: Okay.
- 11:23SPEAKER_01: And these packets carry the helpful signals, proteins, and genetic instructions to further support repair and calm inflammation.
- 11:31SPEAKER_00: I've got an analogy for this.
- 11:32SPEAKER_00: If the stem cells are the emergency managers on the ground, the exosomes are the text messages and emails they send out to coordinate the rescue effort.
- 11:41SPEAKER_01: That is exactly what they are.
- 11:41SPEAKER_01: It's cellular communication.
- 11:43SPEAKER_00: And you can actually get an extra dose of just the messages.
- 11:46SPEAKER_01: Yes.
- 11:46SPEAKER_01: Combining stem cells with an additional infusion of exosomes strengthens the overall supportive care plan.
- 11:53SPEAKER_00: It's like upgrading the bandwidth of the rescue operation.
- 11:56SPEAKER_01: Exactly.
- 11:57SPEAKER_01: It reinforces Cyrnicel's commitment to cutting-edge layered therapies.
- 12:02SPEAKER_01: They aren't just using one tool, they're using the entire toolbox of cellular communication.
- 12:07SPEAKER_00: So to sum this all up for you listening, what we've seen from these sources is that stem cell therapy for liver disease at Cyronacell isn't a miraculous quick fix.
- 12:16SPEAKER_01: Definitely not.
- 12:17SPEAKER_00: It is a deeply scientific, highly supportive program.
- 12:21SPEAKER_00: It utilizes ethically sourced umbilical MSCs to reduce inflammation, promote hepatocyte growth, and stabilize a patient's quality of life.
- 12:30SPEAKER_01: And this raises an important question.
- 12:32SPEAKER_00: Yeah.
- 12:32SPEAKER_01: For decades, modern medicine has treated the human body like a car.
- 12:36SPEAKER_01: You know, when a part breaks, we just assume we have to swap it out with a transplant.
- 12:40SPEAKER_00: Right, replace the part.
- 12:41SPEAKER_01: But as we've learned today from these sources, what if the future of medicine isn't about replacing our organs, but simply learning how to speak the cellular language required to tell them to heal themselves?
- 12:51SPEAKER_01: Wow.
- 12:52SPEAKER_01: Next time you think about medicine, consider that the cure might not be a new part, but a better messenger.
- 12:58SPEAKER_00: That is such a fascinating way to look at it.
- 13:00SPEAKER_00: Thank you so much for breaking all this down.
- 13:02SPEAKER_00: And thank you, the listener, for joining us on this deep dive into the Cirona cell sources.
- 13:07SPEAKER_00: Keep asking questions and seeking out the science behind the headlines.
- 13:10SPEAKER_00: We'll see you next time.